FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	$D \subset$	20540	
wasiiiigtoii,	D.C.	20549	

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APPROVAL									
OMB Number: 3235-0287									
Estimated average burden									
hours per response: 0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Borisy Alexis					2. Issuer Name and Ticker or Trading Symbol Relay Therapeutics, Inc. [RLAY]							(Ch	elationship eck all appli X Directo	cable)	g Pers	son(s) to Iss 10% Ow		
(Last)		,	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 05/31/2023								Officer below)	(give title		Other (s below)	pecify
C/O RELAY THERAPEUTICS, INC. 399 BINNEY STREET, 2ND FLOOR				4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)						Line	Individual or Joint/Group Filing (Check Applicable le) X Form filed by One Reporting Person						
(Street)	IDGE M	A	02139		_									Form filed by More than One Reporting Person				
(City)	(Si	tate)	(Zip)			Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.									d to			
		Tab	le I - Non-	Deriv	ative	Sec	curities	A C	quired, D	isp	osed o	f, or Be	neficial	ly Owned	d .			
1. Title of Security (Instr. 3) 2. Transar Date (Month/Date)					Execution Date,			Transaction Disposed Code (Instr. 5)		ities Acquired (A) or d Of (D) (Instr. 3, 4 and		Benefici	es ally Following	Form	: Direct C · Indirect E str. 4) C	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	Amount	nount (A) or (D)		Transac (Instr. 3	ction(s)			instr. 4)				
		Т	able II - D (e						uired, Dis , options					Owned				
Derivative Conversion Date Security or Exercise (Month/Day/Year)		3A. Deemed Execution D if any (Month/Day/	cution Date, Tr		Transaction Code (Instr.				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Securi (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Code V		(A)	(D)	Date Exercisable		piration te	Title	Amount or Number of Shares						
Stock Option (Right to Buy)	\$11.14	05/31/2023			A		66,055		(1)	05/	/30/2033	Common Stock	66,055	\$0.00	66,055		D	

Explanation of Responses:

1. This option was granted on May 31, 2023 with respect to 66,055 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date.

Remarks:

/s/ Brian Adams, as Attorneyin-Fact ** Signature of Reporting Person

06/01/2023

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.